See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Liberation Day
Tariffs
Donald Trump
Trade War
Baseball
Natural Disasters
Republican Party
US Politics
Social Media
Senate
Democratic Party
U.S.-Canada Relations
Published • loading... • Updated

Zealand's obesity strategy and Immunovant's curious development plan

Summary by STAT
How do obesity biotechs compete against Novo Nordisk and Eli Lilly? Why does gene therapy pioneer Jim Wilson think there’s “irrational pessimism” in the field? And why isn’t Immunovant advancing the drug it just reported positive data on? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about positive data from Immunovant’s autoimmune drug candidate, a patient death linked to Sarepta’s ge…

4 Articles

All
Left
Center
1
Right
2
Colorado Springs GazetteColorado Springs Gazette
Reposted by
Denver GazetteDenver Gazette
Lean Right

Gene therapy loses luster as investors eye quicker returns from weight-loss drugs

By Deena Beasley

Read Full Article
STATSTAT
Center

Zealand's obesity strategy and Immunovant's curious development plan

How do obesity biotechs compete against Novo Nordisk and Eli Lilly? Why does gene therapy pioneer Jim Wilson think there’s “irrational pessimism” in the field? And why isn’t Immunovant advancing the drug it just reported positive data on? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about positive data from Immunovant’s autoimmune drug candidate, a patient death linked to Sarepta’s ge…

·Boston, United States
Read Full Article
regionalmedianews.comregionalmedianews.com

Gene therapy loses luster as investors eye quicker returns from weight-loss drugs - Regional Media News

By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward sectors like obesity and cancer, as sales for some of the new treatments fall short. In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene therapy for hemophilia priced at $3.5 million per patient. Bluebird Bio, a gene the…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Right
67% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States on Thursday, March 20, 2025.
Sources are mostly out of (0)

Similar News Topics

Jim Wilson

Jim Wilson

Cancer

Cancer

Obesity

Obesity

Novo Nordisk

Novo Nordisk

Eli Lilly

Eli Lilly

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal